MCL-1 inhibitor antibody conjugates and method of administration
DE602020072036T2Active Publication Date: 2026-05-13LES LAB SERVIER SA +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- LES LAB SERVIER SA
- Filing Date
- 2020-05-19
- Publication Date
- 2026-05-13
AI Technical Summary
Technical Problem
Current cancer treatments face challenges due to Mcl-1 overexpression leading to drug resistance and tumor cell survival, as well as the need for targeted therapies that can effectively inhibit Mcl-1 to induce apoptosis in cancer cells.
Method used
Development of antibody-drug conjugates (ADCs) that combine an Mcl-1 inhibitor with an anti-CD74 antibody, allowing for targeted delivery and internalization into cancer cells, thereby inhibiting Mcl-1 and inducing apoptosis.
Benefits of technology
The ADCs effectively slow and inhibit tumor growth by specifically targeting and killing cancer cells, overcoming drug resistance and enhancing treatment efficacy.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.